Small Molecules
5 December 2016
Wilson Therapeutics Announces That WTX101 Meets the Primary Endpoint in Phase 2 Study in Wilson Disease5 December 2016
Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin’s Lymphoma5 December 2016
Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting2 December 2016
NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine2 December 2016
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients2 December 2016
Sunovion Initiates SEP-363856 Phase 2 Program for Patients with Schizophrenia or Parkinson’s Disease Psychosis2 December 2016
GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD1 December 2016
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder1 December 2016
Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil1 December 2016
Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute LeukemiaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports